Kaplan University nursing alum Debra Eppley was already working in the nursing field when she started her RN-to-Bachelor of Science in Nursing completion program (RN-to-BSN program). Kaplan University’s flexibility and support offered her the opportunity to complete her degree online while continuing to work. Once she completed her Bachelor of Science Nursing online, she was able to make a career move that not only increased her salary, but also her level of job satisfaction.
Kaplan University makes taking online nursing classes a streamlined process. Every day nurses choose Kaplan University for their online master’s degree programs. The distance learning curriculum makes a nursing degree obtainable for working professionals. Nursing as a career is a rewarding occupation that could allow for a wide range of employment opportunities beyond the hospital doors.* The Kaplan University School of Nursing offers online nursing degrees such as an the RN-to- BSN completion program, the RN-to-MSN option, and nurse practitioner certificate programs† to help get you where you want to be. Nursing programs at Kaplan University, including the MSN programs online, are designed for nurses that are already in the field. It’s this unique approach that sets Kaplan University apart.
*Kaplan University's programs are designed to prepare graduates to pursue employment in their field of study, or in related fields. However, the University does not guarantee that graduates will be placed in any particular job, eligible for job advancement opportunities, or employed at all. Additional training or certification may be required.
† At this time, the nurse practitioner certificates are available only in the following states: California, Connecticut, Delaware, Florida, Iowa, Michigan, Mississippi, Montana, Oklahoma, Rhode Island, South Carolina, South Dakota, and Vermont.
“I got out of high school and started working. I had a family very young. About the time I was 28 I decided I needed to go to school. I went and got my associate’s degree in nursing at that time. I had worked in labor and delivery, and that’s my niche. I like it–I like babies, I like seeing families with their babies. Then I thought, I love floor nursing but there was something else I wanted to do.
We are in Coshocton, Ohio, which is very near to the heart of Amish country. I just needed to step out and do something else for myself. What I thought I would like to do required a bachelor’s degree and so I started looking down that road. I had kind of shopped around on the net looking for every last online class. You’re looking at price, you’re looking at length, you’re looking at what kind of clinical requirements are there–especially for me in nursing. I just started weeding and narrowing it down and I kept coming back to Kaplan University because it seemed to fit what I wanted to do at that time.
I enrolled to start my bachelor’s degree. There were times when I thought I was going to quit–family life is too much, work is too much, school is too much. I thought, no wasn’t an option. But of course that thought of having that extra two year degree bumps that salary up immensely. I was also thinking, ‘I’m going to have four kids I have to put through college, because now I’m encouraging them to go to college so I need to find a way to help them pay for that, too.
Financially going back to school was a huge plus. This January the head of OB at the time decided to leave her position, and it was open. They posted the job and I debated long and hard because I thought, ‘It’s too soon,’ ‘I can’t be there yet,’ and after much coaxing from a few of my coworkers, my husband, and my mother, I went ahead and I applied for the job and they hired me.
I started the end of March; I am now the OB coordinator, so I manage the whole OB department. It’s just a huge feeling of pride. My Kaplan [University] experience was fantastic. They just want to see you succeed and they want to help you get there. You have a job, you have a
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Nestlé Health Science will unveil its pediatric closed system formulas with the new SpikeRight® PLUS port at the annual American Society for Parenteral and Enteral Nutrition’s (A.S.P.E.N.) Clinical Nutrition Week meeting being held in Orlando January 21-24. The introduction marks a significant step in supporting the provision of safe enteral (tube) feeding.
Enteral tubing misconnections, where feeding solutions are wrongly administered through intravenous (IV) tubing or other non-enteral systems, have been a concern for nearly thirty years. Most commonly occurring in intensive care settings, where patients have multiple types of tubing connections, an enteral tubing misconnection can result in catastrophic complications and possibly death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53580-nestle-health-science-launches-next-generation-spikeright-plus-pediatrics
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine, highlight updated management recommendations for patients with acute gout. These new recommendations come at a time when the incidence of gout is soaring; 8.3 million Americans are estimated to be gout patients.
Instead of challenging, restrictive dieting, patients are encouraged to consume a balanced diet of fresh fruit and vegetables, low-fat dairy products, nuts and grains. More importantly, patients should limit their intake of high fructose corn syrup, a common ingredient in many processed foods and drinks, and purine-rich foods, particularly red meat, beer and shellfish.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56234-gout-uric-acid-education-arthritis-lifestyle-change-treatment-options
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that subscribers to Epilog.us can now access the latest information related to Practice Management & Epilepsy at http://www.Epilog.us. Led by Dr. Aatif Husain, Director of the Clinical Neurophysiology Fellowship, Professor of Medicine, Division of Neurology, Duke University Medical Center, and Dr. John Stern, Co‐Director of the Seizure Disorder Center and Professor of Neurology at the David Geffen School of Medicine at UCLA, areas of focus include: the importance of billing code accuracy; commonly utilized billing codes in epilepsy and neurology; and epilepsy quality measures from the American Academy of Neurology (AAN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58062-upsher-smith-epilog-us-practice-management-epilepsy-resources-available
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
